Relevant bibliographies by topics / Immunosuppression / Books

Books on the topic 'Immunosuppression'

To see the other types of publications on this topic, follow the link: Immunosuppression.
Author: Grafiati
Published: 4 June 2021
Last updated: 30 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 books for your research on the topic 'Immunosuppression.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Thomson, Angus W., ed. Therapeutic Immunosuppression. Dordrecht: Springer Netherlands, 2001. http://dx.doi.org/10.1007/978-94-010-0765-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Eisen, Howard J., ed. Pharmacology of Immunosuppression. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-05118-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Cochat, P., J. Traeger, C. Merieux, and M. Derchavane, eds. Immunosuppression under Trial. Dordrecht: Springer Netherlands, 1999. http://dx.doi.org/10.1007/978-94-011-4643-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Specter, Steven, Mauro Bendinelli, and Herman Friedman, eds. Virus-Induced Immunosuppression. Boston, MA: Springer US, 1989. http://dx.doi.org/10.1007/978-1-4684-5583-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Taylor, Charles B. Immunosuppression: New research. New York: Nova Biomedical Books, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Steven, Specter, Bendinelli Mauro, and Friedman Herman 1931-, eds. Virus-induced immunosuppression. New York: Plenum Press, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Naor, David, Benjamin Y. Klein, Nora Tarcic, and Jonathan S. Duke-Cohan. Immunosuppression and Human Malignancy. Totowa, NJ: Humana Press, 1990. http://dx.doi.org/10.1007/978-1-4612-4496-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

David, Naor, ed. Immunosuppression and human malignancy. Clifton, N.J: Humana Press, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

W, Thomson Angus, ed. The Molecular biology of immunosuppression. Chichester: Wiley, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Gruber, Scott A. Local Immunosuppression of Organ Transplants. Berlin, Heidelberg: Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-662-22105-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Szekeres-Bartho, Julia. Immunosuppression by progesterone in pregnancy. Boca Raton: CRC Press, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
12

Gruber, Scott A. Local immunosuppression of organ transplants. New York: Chapman & Hall, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
13

L, Adorini, ed. Selective immunosuppression: Basic concepts and clinical applications. Basle: Karger, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
14

Diego, Calif ). International Congress on Immunosuppression (2nd 2001 San. The 2nd International Congress on Immunosuppression: December 6-8, 2001, San Diego Marriott Hotel & Marina, San Diego, California, USA : program and abstracts. Secaucus, N.J: Professional Postgraduate Services/Thomson Healthcare, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
15

1958-, Hakim Nadey S., ed. Current immunosuppression: An update : proceedings of a round table meeting held in Prague on 6th December 1996. London: Royal Society of Medicine Press, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
16

Norbert, Gilmore, Wainberg Mark A, Medical Research Council (Canada), Canada. National Advisory Committee on AIDS., and Workshop on Viral Mechanisms of Immunosuppression (1984 : Montréal, Quebec), eds. Viral mechanisms of immunosuppression: Proceedings of a workshop. New York: Liss, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
17

José, Strauss, and Strauss Louise, eds. Growth, immunosuppression, and renal disorders in neonates and children: Current concepts in diagnosis and management. Coral Gables, Fla: University of Miami Press, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
18

Bray, Peter William. Allograft microvascular epiphyseal plate transplants with short-term immunosuppression. Ottawa: National Library of Canada, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
19

J, Klastersky, ed. Infectious complications of cancer. Boston: Kluwer Academic Publishers, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
20

B, Vogelsang Georgia, and Pavletic Steven, eds. Chronic graft versus host disease: Interdisciplinary management. Cambridge [England] ; New York: Cambridge University Press, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
21

J, Smialowicz Ralph, and United States. Environmental Protection Agency, eds. Comparative immunosuppression of various glycol ethers orally administered to Fischer 344 rats. [Washington, D.C.?: U.S. Environmental Protection Agency, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
22

Schapira, David V. The diagnosis and management of the cancer patient with sepsis. New York, NY: Biomedical Information Corp., 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
23

C, Tetta, ed. Immunopharmacology of the renal system. London: Academic Press, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
24

Kuypers, Dirk R. J., and Maarten Naesens. Immunosuppression. Edited by Jeremy R. Chapman. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0281_update_001.

Full text
Abstract:
Combination immunosuppressive therapy produces excellent short-term results after kidney transplantation. Long-term graft survival has improved, but less dramatically. Death with a functioning graft remains the primary cause of graft loss. Dosing of current immunosuppressive therapy balances between careful clinical interpretation of time-driven immunological risk assessments and drug-related toxicity on the one hand, and the use of simple surrogate drug exposure indicators like blood/plasma concentrations on the other. The combined use of calcineurin-inhibitors (CNIs) with mycophenolic acids and corticosteroids has been fine-tuned over the last decade, based on empirically derived observations as well as on the results of large multicentre randomized clinical studies. Corticosteroid withdrawal and avoidance are feasible, at least in patients with a low immunological risk, but CNI-free protocols have had few long-term successes. Some minimization strategies have increased risk of developing acute rejection or (donor-specific) anti-HLA antibodies, with deleterious effects on the graft. Mammalian target of rapamycin inhibitors (mTORi) have shown limited benefit in early CNI replacement regimens and their long-term use as primary drug is hampered by intolerance. In the setting of particular malignant disease occurring after transplantation, such as squamous cell carcinoma of the skin and Kaposi’s sarcoma, mTORi seem promising. Induction agents (anti-interleukin 2 receptor monoclonal antibodies, antithymocyte globulins) effectively diminish the risk of early immunological graft loss in recipients with moderate to high immunological risk but at the price of more infectious or malignant complications. While personalized transplantation medicine is only in its early stages of development, attempts are made to quantitatively measure the clinical degree of immunosuppression, to tailor immunosuppressive therapy more specifically to the patient’s individual profile, and to monitor graft status by use of invasive (e.g. surveillance renal biopsies) and non-invasive biomarkers. These scientific endeavours are a necessity to further optimize the current immunosuppressive therapy which will remain for some time to come.
APA, Harvard, Vancouver, ISO, and other styles
25

He, Xuehui, ed. Immunosuppression. IntechOpen, 2020. http://dx.doi.org/10.5772/intechopen.87403.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

He, Xuehui. Immunosuppression. IntechOpen, 2020.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
27

Therapeutic Immunosuppression (Immunology and Medicine, Volume 29). Springer, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
28

Thomson, A. W. Therapeutic Immunosuppression. Ingramcontent, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
29

Thomson, A. W. Therapeutic Immunosuppression. Springer, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
30

Specter, Steven, Herman Friedman, and Mauro Bendinelli. Virus-Induced Immunosuppression. Springer, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
31

Specter, Steven, Herman Friedman, and Mauro Bendinelli. Virus-Induced Immunosuppression. Springer, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
32

Wijdicks, Eelco F. M., and Sarah L. Clark. Immunosuppression and Immunotherapy. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190684747.003.0010.

Full text
Abstract:
Immune modulation in the neurosciences intensive care unit mostly involves high-dose corticosteroids, plasma exchange, and immunoglobulin. Corticosteroids are frequently used in patients with neurologic complications of cancer. Neurosurgeons typically use corticosteroids after performing a craniectomy to reduce cerebral edema. Corticosteroids are the established initial treatment modality of choice for patients with acute metastatic epidural spinal cord compression. Therapeutic apheresis or immunoglobulin is generally used as supportive therapy in patients with Guillain-Barré syndrome, myasthenia crisis, and autoimmune encephalitis. Immune modulation has been considered essential in autoimmune encephalitis despite lack of controlled clinical trials. In these now better characterized disorders, a combination of corticosteroids, intravenous immune globulin (IVIG), plasma exchange, rituximab, or cyclophosphamide are used. The use of acute immunotherapy and precautionary measures are discussed in this chapter.
APA, Harvard, Vancouver, ISO, and other styles
33

Pharmacology of Immunosuppression. Springer International Publishing AG, 2023.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
34

Eisen, Howard J. Pharmacology of Immunosuppression. Springer International Publishing AG, 2022.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
35

Ginns, Leo C. Immunosuppression In Transplantation. Blackwell Publishing, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
36

Cochat, Pierre. Immunosuppression Under Trial. Springer, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
37

Virus-Induced Immunosuppression. Island Press, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
38

Tyagi, Rajeev K., and Prakriti Sharma. Immunosuppression and Immunomodulation. IntechOpen, 2023.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
39

Carmona, Loreto, and Maria Galindo. Perioperative management of immunosuppression. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0093.

Full text
Abstract:
Many rheumatologists are concerned about the complications of maintaining immunosuppression at the time of elective surgery. Complications may be increased risk of infection, or a slow healing of the surgical wound. On the other hand, stopping medication may place the patient at undesirable levels of disease activity. Many rheumatologists actually act on art, stopping the drug perioperatively depending on blood count, drug type and dose, previous postoperative complications, type of surgery, and other factors. The timing of stopping treatment preoperatively and restarting after surgery also significantly differ among rheumatologists. All in all, there is a great variability in clinical practice related to the perioperative use of immunosuppressants. This chapter reviews the evidence on methotrexate, glucocorticoids, and biological therapies related to the perioperative period, and it proposes some recommendations on the management of immunosuppressant drugs in rheumatic diseases. Factors that may be related to complications will also be reviewed.
APA, Harvard, Vancouver, ISO, and other styles
40

Carmona, Loreto, and Maria Galindo. Perioperative management of immunosuppression. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199642489.003.0093_update_003.

Full text
Abstract:
Many rheumatologists are concerned about the complications of maintaining immunosuppression at the time of elective surgery. Complications may be increased risk of infection, or a slow healing of the surgical wound. On the other hand, stopping medication may place the patient at undesirable levels of disease activity. Many rheumatologists actually act on art, stopping the drug perioperatively depending on blood count, drug type and dose, previous postoperative complications, type of surgery, and other factors. The timing of stopping treatment preoperatively and restarting after surgery also significantly differ among rheumatologists. All in all, there is a great variability in clinical practice related to the perioperative use of immunosuppressants. This chapter reviews the evidence on methotrexate, glucocorticoids, and biological therapies related to the perioperative period, and it proposes some recommendations on the management of immunosuppressant drugs in rheumatic diseases. Factors that may be related to complications will also be reviewed.
APA, Harvard, Vancouver, ISO, and other styles
41

Personalized Immunosuppression in Transplantation. Elsevier, 2016. http://dx.doi.org/10.1016/c2013-0-19247-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Immunosuppression and Human Malignancy. Humana Press, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
43

Naor, David, Benjamin Y. Klein, Nora Tarcic, and Jonathan S. Duke-Cohan. Immunosuppression and Human Malignancy. Humana Press, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
44

Naor, David, Benjamin Y. Klein, Nora Tarcic, and Jonathan S. Duke-Cohan. Immunosuppression and Human Malignancy. Humana Press, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
45

Gruber, Scott A. Local Immunosuppression of Organ Transplants. Springer, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
46

Immunosuppression and Immunomodulation [Working Title]. IntechOpen, 2023. http://dx.doi.org/10.5772/intechopen.102203.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Szekeres-Bartho, Julia. Immunosuppression by Progesterone in Pregnancy. Taylor & Francis Group, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
48

Hartung, H. P. Selective Immunosuppression (Neuroscience Intelligence Unit). Springer-Verlag Berlin and Heidelberg GmbH & Co. K, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
49

Noonan, F. Uv-B Radiation and Immunosuppression. Chapman & Hall, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
50

Gruber, Scott A. Local Immunosuppression of Organ Transplants. Springer London, Limited, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Immunosuppression' for other source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography